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and mortality adjusting for patient factors. 
Results: Most patients underwent PCI at high (n=49,429, 42.6%) or very high 
(n=48,517. 41.9%) volume hospitals; few patients were treated at low (n=4,355, 3.8%) or 
medium (n=l3,609, 11.7%) volume hospitals. Crude in-hospital mortality rates differed 
for patients treated at low and very high volume hospitals (2.82% vs. 1.41%, p<O.OOl), 
but were comparable among patients treated at medium and high volume hospitals 
(1.75% vs. 1.68%. p=O.56). The multivariate adjusted odds of in-hospital mortality were 
similar for patients treated in medium (odds ratio [OR] 0.95, 95% confidence interval [Cl] 
0.76-l .17), high (OR 1.00, referent), and very high volume hospitals (OR 0.96, 95% Cl 
0.83-l .lO). Patients treated at low volume hospitals were at increased risk of mortality 
(OR 1.37, 95% Cl 1.08-l .74). 
Conclusion: Although based on administrative data, our analysis found no evidence of 
higher in-hospital mortality among patients undergoing PCI at medium volume hospitals 
(ZOO-399 cases) compared with patients treated at hospitals with annual PCI volumes of 
400-999 cases. suggesting the ACC/AHA PCI hospital volume minimum may merit 
reevaluation. 
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Background: Studies examining costs following myccardial infarction (Ml) have been 
limited by short follow-up, small sample sizes, restricted patient populations, or failure to 
include hospital (H), physician (P), or market (M) characteristics. In a national sample 
with extensive supplemental data, we sought to identify the factors associated with costs 
in the year following Ml. 
Methods: 84,373 elderly acute Ml patients (90% white, 49% female) in the Cooperative 
Cardiovascular Project were linked to Medicare Part A claims, AHA Hospital Surveys, the 
CMS directory of physician specialties, and the CMS Hospital Wage Index File. Medicare 
charges were converted to costs using institutional cost to charge ratios. Associations 
with admission episode and one-year log-transformed costs were assessed by ragres- 
sion analysis with robust standard errors. 
Results: Mean cost was $12,956 (median $6,633) for the admission episode and 
$19,597 (median $13,583) at one year. Patient characteristics only accounted for 11% of 
the admission and one-year cost variation. Patient variables most highly associated with 
one-year costs included anterior Ml ($1455 more), CHF (51858 more), and COPD 
($1894 more). Older age (age 2 80 years) was most strongly associated with lower costs 
($5693 less). After adding HPM variables, the models explained 22% of admission and 
17% of the one-year cost variation. After adding treatment and outcome variables, the 
models explained 55% of the admission and 59% of the one-year cost variation. The 
variables most highly associated with one-year costs were procedures including echo 
($4261 more), thrombolysis ($3856 more), catheterization (514,064 more), PCI ($8,264 
more), and CABG ($24,622 more). While patient death was associated with lower admis- 
sion episode costs, it was also associated with higher one-year costs. 
Conclusion: In models including patient, HPM, care, and outcomes data, cardiac proce- 
dures account for the largest share of admission and one-year health care cost variation. 
These data indicate that strategies focusing on appropriate procedure use have the 
greatest potential to produce important cost savings. 
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Background: The CURE trial showed a relative risk of 0.8 of suffering from stroke, myo- 
cardial infarction (Ml) or cardiovascular death in patients treated with Clopidogrel + ASA 
compared to ASA alone. The purpose of this study was to evaluate the cost-effective- 
ness in terms of cost per life year gained (LYG) of this treatment in Sweden. 
Methods: A Markov model with six states (at risk, first year with stroke, following years 
with stroke, first year with new MI, following years with new MI and death) was used. The 
risk of suffering stroke, Ml or cardiovascular death for patients hospitalized with unstable 
angina was calculated based on data from the Swedish inpatient and causes of death 
registers using logistic and W&bull regressions. Mortality was estimated using data from 
the same sources. Intervention was studied for a period of 12 months (maximum tollow- 
up in the trial), and the intervention costs and effect was annualized based on the 9- 
month average follow-up in the CURE trial. Costs (direct, indirect and costs in added 
years of life) due to different events were taken from published sources, while cost for the 
initial hospitalization was estimated based on data from the CURE trial. In the base-case, 
simulations were performed for a 64-year old cohort consisting of 61.3 % men (similar to 
that of the trial). LYG was used as the measure of effectiveness. Cost and effects were 
discounted at 3%. 
Results: The model predicts an incremental survival of 0.12 years and incremental direct 
costs of 149 US$ per patient. Including indirect costs and costs in added years of life the 
incremental cost IS 1,959 US$. The treatment is cost-saving if costs in added years of life 
are excluded. The incremental cost-effectiveness ratio is thus 1,290 US$/LYG or 15,199 
US$/LYG depending on perspective. Using the upper bound of the 95% Cl of the relative 
risk in the trial. the ratios are 4,942 US$/LYG and 20,382 US$/LYG. Older patients show 
more favorable ratios than younger ones when considering direct costs only, while the 
opposite is true when all costs are included. 
Conclusion: Clopidogrel + ASA compared to ASA alone in this indication shows a favor- 
able cost-effectiveness ratio compared with other cardiovascular therapies. 
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Background: Past studies evaluating the effect of gender on percutaneous coronary 
intervention (PCI) outcomes in patients with AMI have shown conflicting results. It has 
also been suggested that younger, but not older, women represent a high risk group for 
coronary interventions. 
Objective: To determine whether women have a greater risk for in-hospital mortality in 
younger, but not in older patients. 
Methods: The study population included 59,792 cases with AMI who underwent PCI in 
223 hospitals participating in the ACC-NCDR from l/l/98 to 9/30/2001. Logistic regres- 
sion models ware fit using over 30 demographic, clinical, and angiographic variables to 
assess the effect of female gender on risk adjusted in-hospital mortality. The interaction 
between age in lo-year increments and gender was assessed with the Breslow-Day test 
(unadjusted) and likelihood ratio test (adjusted). 
Results: 19,292 (32.3%) of the cases were women. Although the unadjusted relative risk 
ot death for females compared to males was higher in the younger than in the older 
patients, the excess risk for women at younger ages was explained by differences in 
comorbid diseases and clinical severity between younger men and women. Overall after 
multivariate adjustment women had a 32% higher mortality risk compared with men. 
Conclusions: Women undergoing PCI after AMI, overall, have a higher risk of In-hospi- 
tal mortality than men. The effect of gender does not vary across age after accounting for 
differences in clinical risk and comorbid illness. 
Effect of Gender on In-Hospital Mortality by Age Group 
Overa Age< Age Age Age Age Interacti 
II 50 50-59 60-69 70-79 >=80 on p 
Value 
Number of cases 59,742 11,214 15,517 14,345 12,861 5.805 
Unadjusted Odds 1.79 1.92 1.68 1.15 1.21 1.14 0.02 
Ratio (95% (1.64- (1.27- (1.31- (0.95. (1.05- (0.X- 
Confidence Interval) 1.94) 2.69) 2.15) 1.39) 1.40) 1.36) 
Adjusted Odds Ratio 1.32 1.23 1.55 1.16 1.34 1.36 ns 
(95% Confidence (1.19. (0.79. (1.18- (0.93. (1.14- (l.l- 
Interval) 1.46) 1.92) 2.02) 1.43) 1.58) 1.67) 
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Background: While multiple observational studies have characterized the use of ew- 
dew?-based therapies for patients with ST-segment elevation myocardial infarction 
(STEMI), the care of patients with non-ST-segment elevation Ml (NSTEMI) has not been 
as well-described. 
Methods: Treatments used for patients wth acute Ml from the National Registry of Myo- 
cardial Infarction (NRMI)-4 (June, 2OOQ - June, 2002) during the initial hospitalization 
were analyzed. Patients who were transferred-in from another hospital and those who 
were transferred-out were excluded. Acute (within 24 hours of presentation) and dis- 
charge care for “ideal’ patients without contraindlcations to the given therapies were 
compared for patients with STEMI vs. NSTEMI. 
Results: A total of 185,968 patients from 1,247 U.S. hospitals ware included in the anal- 
ysis. Approximately 71% of the patients presented with NSTEMI. 
Conclusions: Despite higher-risk clinical characteristics, patients with NSTEMI are 
treated less aggressively than patients with STEMI. However, evidence-based therapies 
are underused for all patients with acute Ml and in-hospital mortality rates are substan- 
tially higher than those seen in clinical trial populations. 
